Back to News
Market Impact: 0.1
Eli Lilly To Showcase Retatrutide, Foundayo & EloraTZP Data At EASD 2026
Source: Nasdaq
Healthcare & Biotech
Eli Lilly announced it will present new data from its cardiometabolic portfolio at the European Association for the Study of Diabetes annual meeting in Milan from September 28 to October 2, 2026. The announcement provides no clinical results, product-specific updates, or financial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
LLY0.20
More News
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat
- Freedom Broker raises Eli Lilly stock price target on GLP-1 demand
- Tech gets crushed, defensive stocks shine. How we're making sense of it all
- Jim Cramer's top 10 things to watch in the stock market Friday
- Illumina CEO on Q3 Results and Business Outlook
- UnitedHealth is finally getting its act together. I'm buying into the turnaround